Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 3/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183606 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL5156869 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL475744 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL30720983 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL29040317 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL475745 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL859599 | 1.00 | FFAR2 (0.51) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL28511990 | 0.90 | ABCB1 (0.49) | FFAR2ABCB1RIPK1GPR119 | |
| SCHEMBL4870228 | 0.90 | ABCB1 (0.52) | ABCB1RIPK1GPR119 | |
| SCHEMBL14074143 | 0.90 | ABCB1 (0.52) | ABCB1RIPK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-1997533-B1 | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | PHENOMIX CORP (US) | 2014-09-24 | — | — | EP | disclosed |
| CN-101362773-B | Heterocyclic boronic acid compounds | PHENOMIX CORP | 2013-07-24 | — | — | CN | disclosed |
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| CN-1894261-B | Heterocyclic boronic acid compounds | PHENOMIX CORP | 2012-12-05 | — | — | CN | disclosed |
| US-7820680-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1725102-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1743676-A1 | Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors | Phenomix Corporation (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1689757-A4 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORP (US) | 2007-01-10 | — | — | EP | disclosed |
| CN-1894261-A | Heterocyclic boronic acid compounds | PHENOMIX CORP (US) | 2007-01-10 | — | — | CN | disclosed |
| EP-1725102-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1689757-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | Phenomix Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005092099-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005047297-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-5610144-A | CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | FFAR2 636/4885ABCB1 396/4885RIPK1 1244/4885 |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | FFAR2 4001/4885ABCB1 129/4885RIPK1 4414/4885 |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | DPP4, DPP7, DPP3 | FFAR2 169/4885ABCB1 307/4885RIPK1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.